cend-1 + cend-2

CDP1 + TIP is an experimental combination therapy consisting of two tumor-penetrating peptides, CEND-1 (formerly CDP1) and CEND-2 (formerly TIP), developed by Lisata Therapeutics (formerly Cend Therapeutics). These peptides are designed to exploit the CendR (C-end Rule) pathway to enhance the delivery of co-administered chemotherapy or other anti-cancer agents into the dense stroma of solid tumors. CEND-1 is a cyclic iRGD peptide that first binds to alpha-v integrins on the tumor vasculature and is then proteolytically cleaved to reveal a C-terminal R/KXXR/K motif. This motif binds to neuropilin-1 (NRP1), initiating an endocytic/exocytic transport process that moves the peptide and its 'bystander' drugs deep into the tumor tissue. TIP (CEND-2) similarly targets the NRP1 pathway to facilitate tumor penetration. The combination is primarily being evaluated for its potential to improve outcomes in patients with difficult-to-treat solid tumors, such as pancreatic ductal adenocarcinoma, by increasing the local concentration of standard-of-care drugs like gemcitabine and nab-paclitaxel.

Other names

CendR Delivery Peptide 1Tumor-Infiltrating PeptideiRGD peptide